ReVance Therapeutics, Inc. Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Over-Allotment Option

Published: Feb 12, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEWARK, Calif., Feb. 11, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the closing of its initial public offering of 6,900,000 shares of common stock at a public offering price of $16.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares of common stock at the same price to cover over-allotments. Gross proceeds from the sale of the shares is approximately $110 million. The net proceeds from the sale of the shares, after deducting the underwriters' discount and other estimated offering expenses will be approximately $98.7 million.

Help employers find you! Check out all the jobs and post your resume.

Back to news